Despite increasing chemoradiotherapy treatment, there is a paucity of information regarding the effects of radiation exposure on ambulatory infusion pumps used to deliver chemotherapy or other ...
The Diabetes Control and Complications Trial research group documented that low glycosylated hemoglobin (HbA1c) levels were associated with reduced onset and progression of microvascular complications ...
New York, July 19, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Infusion Pumps and Devices: Technologies and Global Markets" - https ...
Continuous subcutaneous insulin infusion (CSII, or insulin pump therapy) reduces HbA1c levels and hypoglycaemia in patients with type 1 diabetes mellitus (T1DM) compared with multiple daily insulin ...
Continuous subcutaneous insulin infusion (CSII) has become an indispensable modality in the management of type 1 diabetes. This therapy employs an insulin pump to deliver both basal and bolus doses, ...
Dublin, Oct. 17, 2022 (GLOBE NEWSWIRE) -- The "Infusion Pumps and Devices: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. This report aims to provide a ...
The following insulin pump models are currently available: Animas 2020 (Animas, Johnson & Johnson, costing £2,600), Paradigm real-Time mmT-522 (Medtronic, costing £2,750), Paradigm real-Time mmT-722 ...
Zealand Pharma has opened up a new frontier for its struggling glucagon analog dasiglucagon, linking the pump-delivered therapy to improved outcomes in kids with congenital hyperinsulinism (CHI) in a ...
The NDA for SPN-830 is supported by data from an extensive development program that includes the phase 3 TOLEDO study and a supportive open-label study. The New Drug Application (NDA) for SPN-830 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results